{"id":477064,"date":"2020-03-31T19:12:02","date_gmt":"2020-03-31T19:12:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=477064"},"modified":"2020-03-31T19:12:02","modified_gmt":"2020-03-31T19:12:02","slug":"prurigo-nodularis-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/prurigo-nodularis-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_477064.html","title":{"rendered":"Prurigo Nodularis Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight"},"content":{"rendered":"
\"Prurigo<\/a><\/div>\n

(Albany, US) DelveInsight has launched a new report on Prurigo Nodularis Market Insights, Epidemiology and Market Forecast-2030<\/strong><\/p>\n

DelveInsight’s “Prurigo Nodularis – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Prurigo Nodularis, historical and forecasted epidemiology as well as the Prurigo Nodularis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

The Prurigo Nodularis market report provides current treatment practices, emerging drugs, Prurigo Nodularis market share of the individual therapies, current and forecasted Prurigo Nodularis market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Prurigo Nodularis treatment practice\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.<\/p>\n

Prurigo Nodularis (PN), one of the various subtypes of prurigo, is a chronic, bothersome-to-debilitating disease of the skin, usually seen as multiple, intensely pruritic, and excoriated nodules erupting on the surfaces of the extremities with intense itching or rubbing. PNs are cutaneous lesions often produced by repetitive scratching; hence the nickname “picker’s nodules”, which may occur as a sequel to chronic pruritus or neurotic excoriations. After establishing a perpetual itch-scratch cycle, lichenification of the skin may ensue, resulting in chronic dermatitis termed lichen simplex chronicus. Several lesions in different stages and sizes, may co-exist in patients with chronic pruritus, which were induced by chronic scratching.<\/p>\n

\"\"<\/p>\n

 <\/p>\n

Request for :- Prurigo Nodularis free sample page<\/a><\/strong><\/p>\n

Epidemiology<\/strong><\/p>\n

The Prurigo Nodularis epidemiology division provide insights about historical and current Prurigo Nodularis patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.<\/p>\n

Report Key facts:- <\/strong><\/p>\n

1. <\/strong>As per the study conducted by Mullins et al. (2019), a majority of patients with prurigo nodularis were present between ages 51 and 65, though several cases in other age groups have also been described. It seems to be more frequent and more intense in females than in males. It is seen as one of the clinical presentations of adult-onset atopic dermatitis. In HIV positive patients, prurigo nodularis is predictive of advanced immunosuppression.<\/p>\n

2. As per DelveInsight’s analysis, it has been observed that most of the patients with Atopic PN account for ~75% of the total diagnosed PN cases, followed by Nonatopic PN (~25%) in the United States. In 2017, there were 116,653 Atopic PN and 38,884 Nonatopic PN patients<\/p>\n

Major key companies working on Prurigo Nodularis that are given below:- <\/strong><\/p>\n

1. Sanofi Pharma Co. <\/span><\/p>\n

2. Trevi Therapeutics <\/span><\/span><\/p>\n

Name of drugs covered are given below:- <\/strong><\/p>\n

1. <\/strong>Dupilumab<\/p>\n

2. Nalbuphine ER <\/span><\/p>\n

Table of content<\/strong><\/em><\/p>\n

1. Key Insights<\/span><\/p>\n

2. Executive Summary of Prurigo Nodularis<\/span><\/p>\n

3. Competitive Intelligence Analysis for Prurigo Nodularis<\/span><\/p>\n

4. Prurigo Nodularis: Market Overview at a Glance<\/span><\/p>\n

4.1. Prurigo Nodularis Total Market Share (%) Distribution in 2017<\/span><\/p>\n

4.2. Prurigo Nodularis Total Market Share (%) Distribution in 2030<\/span><\/p>\n

5. Prurigo Nodularis: Disease Background and Overview<\/span><\/p>\n

6. Patient Journey<\/p>\n

7. Prurigo Nodularis Epidemiology and Patient Population<\/span><\/p>\n

8. Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n

8.1. Prurigo Nodularis Treatment and Management<\/span><\/p>\n

8.2. Prurigo Nodularis Treatment Algorithm <\/span><\/p>\n

9. Unmet Needs<\/span><\/p>\n

10. Key Endpoints of Prurigo Nodularis Treatment<\/span><\/p>\n

11. Marketed Products<\/span><\/p>\n

12. Emerging Therapies<\/p>\n

13. Prurigo Nodularis: Seven Major Market Analysis<\/p>\n

14. Attribute analysis<\/p>\n

15. 7MM: Market Outlook<\/span><\/p>\n

16. Access and Reimbursement Overview of Prurigo Nodularis<\/p>\n

17. KOL Views<\/span><\/p>\n

18. Market Drivers<\/span><\/p>\n

19. Market Barriers<\/span><\/p>\n

20. Appendix<\/span><\/p>\n

20.1. Bibliography<\/span><\/p>\n

20.2. Report Methodology<\/span><\/p>\n

21. DelveInsight Capabilities<\/span><\/p>\n

22. Disclaimer<\/span><\/p>\n

23. About DelveInsight<\/a><\/p>\n

Why should you buy this report?<\/strong><\/p>\n